173 related articles for article (PubMed ID: 20737746)
1. Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers.
Sudoyo AW
Acta Med Indones; 2010 Jan; 42(1):45-50. PubMed ID: 20737746
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
3. Factors predicting survival in surgical palliative resection of stage IV colorectal cancer.
Scabini S; Rimini E; Romairone E; Scordamaglia R; Pertile D; Ferrando V
Minerva Chir; 2009 Jun; 64(3):303-6. PubMed ID: 19536056
[TBL] [Abstract][Full Text] [Related]
4. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of mitochondrial mutations in colorectal cancer.
Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
[TBL] [Abstract][Full Text] [Related]
6. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance.
Jantscheff P; Terracciano L; Lowy A; Glatz-Krieger K; Grunert F; Micheel B; Brümmer J; Laffer U; Metzger U; Herrmann R; Rochlitz C
J Clin Oncol; 2003 Oct; 21(19):3638-46. PubMed ID: 14512395
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
[TBL] [Abstract][Full Text] [Related]
8. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
9. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
10. [Biomolecular prognostic factors in colorectal cancer].
Zorcolo L
Chir Ital; 2006; 58(6):733-42. PubMed ID: 17190278
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients.
Meng WJ; Sun XF; Tian C; Wang L; Yu YY; Zhou B; Gu J; Xia QJ; Li Y; Wang R; Zheng XL; Zhou ZG
Oncology; 2007; 72(1-2):82-8. PubMed ID: 18004081
[TBL] [Abstract][Full Text] [Related]
12. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
[TBL] [Abstract][Full Text] [Related]
14. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
17. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
Niv Y
Isr Med Assoc J; 2005 Aug; 7(8):520-4. PubMed ID: 16106779
[TBL] [Abstract][Full Text] [Related]
18. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy of colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Srp Arh Celok Lek; 1998; 126(11-12):506-11. PubMed ID: 9921027
[TBL] [Abstract][Full Text] [Related]
20. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
